Events & Announcements

DULR Online Presents the JOBS Act Issue

DULR Online is proud to present its JOBS Act Issue. This issue features eight student articles covering different aspects of the Jumpstart Our Business Startups Act, the landmark legislation passed by Congress in 2012 "[t]o increase American job creation and economic growth by improving access to the public capital markets for emerging growth companies." The JOBS Act Issue represents a unique collaboration between the Denver University Law Review, DULR Online, and Professor J. Robert Brown, Jr. Please explore the full issue here.

DU Community Outreach: Student Leaders Develop Program to Connect Diverse High School Students to the Law

On April 20, 2013, the University of Denver Sturm College of Law will host forty-five high school students to participate in Spring Training for Youth and Legal Education (STYLE). STYLE was developed by student leaders of diversity programs at DU Law to connect high school students with the legal profession. The program targets high school students who would not normally have access to the legal community because of their socioeconomic background. The students were nominated by a teacher, counselor, or other community member based on level of motivation and promise. STYLE will introduce the nominated high school students to diverse legal professionals and law students. Students will engage in seminar discussions and participate in a mock trial. The DU Law Review will post select STYLE articles in April.

Volume 91 Board of Editors Announced

Denver University Law Review is excited to announce the Volume 91 Board of Editors.  Please join us in congratulating them in this accomplishment and supporting them in continuing the fine tradition of the Denver University Law Review. Please click here to view the masthead.


Forty Years Since Keyes v. School District No. 1: Equality of Educational Opportunity and the Legal Construction of Modern Metropolitan America

On January 31February 2, 2013,  the Denver University Law Review presented its annual symposium: “Forty Years Since Keyes v. School District No. 1: Equality of Educational Opportunity and the Legal Construction of Modern Metropolitan America.” Emanating from Denver, Colorado, Keyes was the first school-desegregation case from “a major city outside of the South” to reach the United States Supreme Court. The symposium revisited Keyes with key participants from the case and from the court supervision of Denver’s desegregation plan. It looked back at how the city, the metropolitan area, and the state’s public school systems have evolved over the past forty years and considered the challenges they face today and in the future. Click here for more event details, and here for press coverage.


Volume 90 Board of Editors Announced

Denver University Law Review is excited to announce the Volume 90 Board of Editors.  Please join us in congratulating them in this accomplishment and supporting them in continuing the fine tradition of the Denver University Law Review. Please click here to view masthead.


Marijuana at the Crossroads: A Symposium

On January 27, the Denver University Law Review presented our annual symposium. This year we explored the state of medical marijuana laws today, the issues attorneys confront in practice, the constitutional issues, and the ethical issues. For more information, please click here. This event created some buzz with the local media.

Thanks to all our speakers and everyone who worked behind the scenes to help make this a successful event. 


Denver University Law Review Creating a Buzz  

Our most recent issue, Issue 88.4, on Socioeconomic Diversity and American Legal Education is already creating buzz in the legal and education community.

The ABA Journal recently highlighted Richard H. Sander's article "Class in American Legal Education," available here.

In addition, Richard Kahlenberg commented on Prof. Sander's article in The Chronicle of Higher Education blog. Click here to read Prof. Kahlenberg's article on The Chronicle of Higher Education, and here to read Profs. Sander's article and Kahlenberg's reflection. 

Subscriptions and Submissions

For information on how to subscribe to the Denver University Law Review, please click here.

For the guidelines on how to submit an article to Denver University Law Review, please click here. If you would like to submit a shorter piece to DULR Online, please contact the Online Editor at jliles14@law.du.edu.

Sunday
Sep262010

Cannabis as a Medication: Does it Comport with the Modern Scientific Process?

Alice P. Mead†

Modern medicine increasingly seeks to provide treatment approaches that are “evidence based.” Specifically, the Food, Drug, and Cosmetic Act (FDCA) has been developed over the last 100 years to implement cutting-edge scientific knowledge, with the goal of ensuring that new medications are carefully tested for quality, safety, and efficacy. The Food and Drug Administration (FDA), the agency charged with enforcing the FDCA, closely scrutinizes all aspects of medication development.

This system of medication development also enhances and supports the effectiveness of the physician-patient relationship. Medications that successfully pass through this process are accompanied upon marketing by extensive preclinical and clinical testing which provide a robust body of risk/benefit and pharmacological data. Physicians rely upon these data to inform their prescribing decisions and to facilitate informed consent discussions with their patients. 

Furthermore, the FDA process has additional aspects that further protect patient welfare. Medications are approved for marketing only for use in a particular medical condition and by a specified patient population. The FDA requires that manufacturers’ promotional claims be limited to those supported by clinical trial data. Manufacturing facilities are registered with, and inspected by, the FDA to ensure that the manufacturing process is conducted in accordance with validated quality control tools. Medications must be prescribed and dispensed under the supervision of physicians and pharmacists, labeled with instructions for use, and accompanied by information about side effects. While not without its flaws, the FDA process assures the purity, identity, and potency/standardization of products and it is resoundingly supported by all major medical organizations.  

How does “medical marijuana” comport with this FDA paradigm?

Click to read more ...

Saturday
Sep252010

From Proscription to Prescription: America's Maturing Opinion on Marijuana

Robert J. Corry, Jr.  

Travis B. Simpson

Medical marijuana epitomizes the re-maturation of the United States. For the majority of our history, growing and possessing the hemp plant was not only legal, it had been required during notable portions of colonial and wartime history. The Declaration of Independence was printed on hemp paper and a plurality of the Founding Fathers grew hemp on their plantations.

Then, with the onset of the Prohibitionist mentality in the early 20th Century, it was said that a puff of "marihuana" could turn a mild-mannered, law-abiding American into a raving lunatic. Almost seventy-five years later, thousands of people throughout fourteen states use marijuana as a medicine to effectively treat debilitating medical ailments such as cancer, HIV/AIDS, glaucoma, muscular dystrophy, nausea, muscle spasms, and chronic pain.

Click to read more ...

Monday
Aug232010

Cannabis: A Commonwealth Medicinal Plant, Long Suppressed, Now at Risk of Monopolization

Sunil Aggarwal†

Introduction

The acknowledgement that cannabis is a medicinal plant has yet to be made by federal drug regulators. However, in July 2010, the Department of Veterans Affairs, a federal agency, adopted a policy that will formally allow patients treated at its hospitals and clinics to use medical marijuana in the states where it is legal.[1] Additionally, in October 2009, another federal agency, the United States Department of Justice (DOJ), announced that, as a matter of priority, it would endeavor not to target or prosecute those who are using and distributing cannabis in "clear and unambiguous compliance" with state medical-marijuana laws. While both of these policies are fraught with loopholes allowing subjective interpretation, and while they create no new legal rights nor grant any medical patient or provider full legal license to produce, provide, or consume cannabis or other botanical cannabinoid-based medicines, they are landmark steps forward for a federal government that for decades has, as a matter of policy, vehemently denied the fact that cannabis has any redeeming qualities whatsoever and treated it as nothing but highly dangerous, deserving of the strictest prohibition both nationally and globally.

Click to read more ...